These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29550418)

  • 1. SOX9 Transcriptionally Regulates mTOR-Induced Proliferation of Basal Cell Carcinomas.
    Kim AL; Back JH; Chaudhary SC; Zhu Y; Athar M; Bickers DR
    J Invest Dermatol; 2018 Aug; 138(8):1716-1725. PubMed ID: 29550418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MTOR promotes basal cell carcinoma growth through atypical PKC.
    Chow RY; Levee TM; Kaur G; Cedeno DP; Doan LT; Atwood SX
    Exp Dermatol; 2021 Mar; 30(3):358-366. PubMed ID: 33617094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
    Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
    Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
    Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
    Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
    Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
    Buetti-Dinh A; Jensen R; Friedman R
    BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy.
    Sánchez-Danés A; Larsimont JC; Liagre M; Muñoz-Couselo E; Lapouge G; Brisebarre A; Dubois C; Suppa M; Sukumaran V; Del Marmol V; Tabernero J; Blanpain C
    Nature; 2018 Oct; 562(7727):434-438. PubMed ID: 30297799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.
    Bakshi A; Chaudhary SC; Rana M; Elmets CA; Athar M
    Mol Carcinog; 2017 Dec; 56(12):2543-2557. PubMed ID: 28574612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Variations in Histologic Subtypes of Basal Cell Carcinoma.
    Deng M; Marsch AF; Petronic-Rosic V
    Skinmed; 2017; 15(4):265-268. PubMed ID: 28859735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Approaches in Non-Melanoma Skin Cancers-A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC).
    Chmiel P; Kłosińska M; Forma A; Pelc Z; Gęca K; Skórzewska M
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquisition of Drug Resistance in Basal Cell Nevus Syndrome Tumors through Basal to Squamous Cell Carcinoma Transition.
    Jussila AR; Haensel D; Gaddam S; Oro AE
    J Invest Dermatol; 2024 Jun; 144(6):1368-1377.e6. PubMed ID: 38157930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of hedgehog and vitamin D signaling pathways in basal cell carcinomas.
    Albert B; Hahn H
    Adv Exp Med Biol; 2014; 810():329-41. PubMed ID: 25207374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultraviolet damage, DNA repair and vitamin D in nonmelanoma skin cancer and in malignant melanoma: an update.
    Reichrath J; Rass K
    Adv Exp Med Biol; 2014; 810():208-33. PubMed ID: 25207368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hair follicle disruption facilitates pathogenesis to UVB-induced cutaneous inflammation and basal cell carcinoma development in Ptch(+/-) mice.
    Xu J; Weng Z; Arumugam A; Tang X; Chaudhary SC; Li C; Christiano AM; Elmets CA; Bickers DR; Athar M
    Am J Pathol; 2014 May; 184(5):1529-40. PubMed ID: 24631180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKT1 Activation is Obligatory for Spontaneous BCC Tumor Growth in a Murine Model that Mimics Some Features of Basal Cell Nevus Syndrome.
    Kim AL; Back JH; Zhu Y; Tang X; Yardley NP; Kim KJ; Athar M; Bickers DR
    Cancer Prev Res (Phila); 2016 Oct; 9(10):794-802. PubMed ID: 27388747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase.
    Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S; Mu X
    Anticancer Agents Med Chem; 2019; 19(8):1029-1036. PubMed ID: 30827262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.
    Kuonen F; Huskey NE; Shankar G; Jaju P; Whitson RJ; Rieger KE; Atwood SX; Sarin KY; Oro AE
    J Invest Dermatol; 2019 Jul; 139(7):1439-1448. PubMed ID: 30707899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
    Skvara H; Kalthoff F; Meingassner JG; Wolff-Winiski B; Aschauer H; Kelleher JF; Wu X; Pan S; Mickel L; Schuster C; Stary G; Jalili A; David OJ; Emotte C; Antunes AM; Rose K; Decker J; Carlson I; Gardner H; Stuetz A; Bertolino AP; Stingl G; De Rie MA
    J Invest Dermatol; 2011 Aug; 131(8):1735-44. PubMed ID: 21430703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.